{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=46",
    "query": {
      "intervention": "Placebo - saline",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 3542,
    "total_pages": 355,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T23:02:01.329Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00738699",
      "title": "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MORAb-003 (farletuzumab)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Morphotek",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 415,
      "start_date": "2008-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 34,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738699"
    },
    {
      "nct_id": "NCT06577233",
      "title": "Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-28",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-18",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06577233"
    },
    {
      "nct_id": "NCT01006707",
      "title": "Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2010-11",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006707"
    },
    {
      "nct_id": "NCT07246863",
      "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Squamous Non-Small Cell Lung Cancer",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Visugromab RDE (recommended dose for expansion)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Visugromab 6mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Saline Infusion",
          "type": "OTHER"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2025-10-07",
      "completion_date": "2031-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07246863"
    },
    {
      "nct_id": "NCT04584684",
      "title": "Mouth Rinses for Inactivation of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Coronavirus Infection",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "0.9% w/v NaCL Saline",
          "type": "OTHER"
        },
        {
          "name": "1.5% w/v Hydrogen Peroxide",
          "type": "DRUG"
        },
        {
          "name": "0.12% Chlorohexidine Gluconate",
          "type": "DRUG"
        },
        {
          "name": "27% Ethanol plus essential oils",
          "type": "DRUG"
        },
        {
          "name": "0.5% w/v Povidone-iodide",
          "type": "DRUG"
        },
        {
          "name": "0.075% Cetylpyridinium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 128,
      "start_date": "2020-12-18",
      "completion_date": "2021-10-21",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04584684"
    },
    {
      "nct_id": "NCT04502693",
      "title": "Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "rMenB+OMV NZ vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-3",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 3657,
      "start_date": "2020-08-14",
      "completion_date": "2022-09-13",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 64,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04502693"
    },
    {
      "nct_id": "NCT00097838",
      "title": "Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "AVX101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AlphaVax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 96,
      "start_date": "2004-10",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-07-02",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • New York, New York • Rochester, New York + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097838"
    },
    {
      "nct_id": "NCT06896136",
      "title": "Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diarrhea Infectious"
      ],
      "interventions": [
        {
          "name": "VENBETA6890",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Klempner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2025-02-11",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06896136"
    },
    {
      "nct_id": "NCT00496964",
      "title": "Botox for Non-surgical Lateral Release in Patellofemoral Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Patellofemoral Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin A + exercise",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2005-05",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-23",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496964"
    },
    {
      "nct_id": "NCT04966871",
      "title": "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ Challenge (7G8) for CHMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-27",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-11-19T23:02:01.329Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04966871"
    }
  ]
}